AQR Capital Management LLC decreased its position in Amedisys Inc (NASDAQ:AMED) by 71.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,901 shares of the health services provider’s stock after selling 27,872 shares during the period. AQR Capital Management LLC’s holdings in Amedisys were worth $465,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. BlackRock Fund Advisors raised its stake in shares of Amedisys by 6.3% in the third quarter. BlackRock Fund Advisors now owns 2,032,314 shares of the health services provider’s stock worth $96,413,000 after buying an additional 119,553 shares during the period. Wells Fargo & Company MN raised its stake in shares of Amedisys by 3.2% in the third quarter. Wells Fargo & Company MN now owns 1,730,964 shares of the health services provider’s stock worth $82,117,000 after buying an additional 53,652 shares during the period. William Blair Investment Management LLC raised its stake in shares of Amedisys by 46.6% in the fourth quarter. William Blair Investment Management LLC now owns 1,509,937 shares of the health services provider’s stock worth $64,369,000 after buying an additional 480,150 shares during the period. Gilder Gagnon Howe & Co. LLC purchased a new stake in shares of Amedisys during the third quarter worth about $42,527,000. Finally, Northern Trust Corp raised its stake in shares of Amedisys by 1.2% in the third quarter. Northern Trust Corp now owns 765,066 shares of the health services provider’s stock worth $36,295,000 after buying an additional 8,700 shares during the period. Hedge funds and other institutional investors own 94.88% of the company’s stock.
Amedisys Inc (NASDAQ:AMED) opened at 52.54 on Friday. The firm has a 50 day moving average of $50.97 and a 200-day moving average of $45.73. Amedisys Inc has a one year low of $34.58 and a one year high of $55.16. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of 47.76 and a beta of 1.43.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Tuesday, February 28th. The health services provider reported $0.44 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.39 by $0.05. Amedisys had a net margin of 2.93% and a return on equity of 11.94%. The business earned $366.30 million during the quarter, compared to analysts’ expectations of $368.14 million. During the same period in the previous year, the company earned $0.40 earnings per share. Amedisys’s revenue for the quarter was up 8.2% on a year-over-year basis. Equities research analysts forecast that Amedisys Inc will post $2.02 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.themarketsdaily.com/2017/04/21/aqr-capital-management-llc-has-465000-stake-in-amedisys-inc-amed.html.
A number of equities analysts have weighed in on AMED shares. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $59.00 price target (up previously from $50.00) on shares of Amedisys in a report on Friday, March 3rd. Mizuho lifted their price target on shares of Amedisys from $33.00 to $50.00 and gave the company a “neutral” rating in a report on Wednesday, March 1st. Jefferies Group LLC lifted their price target on shares of Amedisys from $50.00 to $57.00 and gave the company a “buy” rating in a report on Wednesday, March 1st. Zacks Investment Research upgraded shares of Amedisys from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a report on Monday. Finally, Benchmark Co. started coverage on shares of Amedisys in a report on Friday, January 27th. They issued a “hold” rating and a $50.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Amedisys currently has an average rating of “Hold” and an average target price of $54.75.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.